For any grade of AEs, the incidence of nausea, anemia, constipation, vomiting, decreased appetite, and fatigue in the Osimertinib therapy subgroup was significantly lower than in the EGFR-TKIs/chemotherapy subgroup. The gene discussed is EGFR; the disease is anemia.